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A method was developed to quantify the "antikeratin-
izing" effects of various retinoids (all-trans-retinoic 
acid, 13-cis-retinoic acid, motretinide, etretinate) in 
rhino mouse skin, which contains many keratinized pi-
losebaceous structures or horn-filled utriculi. Mean utri-
culus diameters in whole mount epidermis were deter-
mined and dose-response relationships were constructed 
after topical or oral administration of test retinoids. All-
trans-retinoic acid was 3.7x, 12.5x, and 50x more po-
tent than 13-cis-retinoic acid, etretinate, and motretin-
ide, respectively, after topical administration. Admin-
istered orally, all-trans-retinoic acid was 2.3x more 
potent than 13-cis-retinoic acid. At 5 mg/kg, each reti-
noid produced a significant reduction in utriculus size. 
The rhino mouse model represents a novel and useful 
assay to quantify anti keratinizing activity and potency 
differences of biologically active retinoids. 
Ret inoids are known to influence cell differentiation [1 - 3] 
and exert profound therapeutic benefits in the treatment of 
acne vulgaris, severe cystic acne, psoriasis, and other disorders 
of keratinization [4- 5]. The usefulness of topical all -trans-
retinoic acid (all-trans-RA, tretinoin) in the treatment of acne 
vulgaris [6,7] and of oral 13-cis- retinoic acid (13-cis-RA, isotre-
tinoin) in cystic acne [8,9) and keratinizing dermatoses [10-
13) is well documented. A new synthetic retinoid, motretinide 
(Ro 11-1430), was reported to be topically efficacious in acne 
vulgaris [14,15], while a close structural analog, etretinate (Ro 
10-9359), has been found to be orally effective in t he treatment 
of severe psoriasis [16,17] and selected disorders of keratiniza-
tion [5,10]. 
A number of in vitro and in vivo assays have provided useful 
information on the modulation of epithelial cell differentiation 
or keratinization by retinoids. Using cultured keratinocytes, 
retinoids were reported to promote desquamation of cells, pre-
vent t heir stratification, and inhibit t he formation of cornified 
envelopes 13,18- 20) . The reversal of keratinization in hamster 
tracheal organ cultures is highly specific for retinoid structures 
and has been used to identify new retinoids for initial biologic 
activity and potency [21]. In the mouse tail scale bioassay 
[22], a variety of retinoids were found to produce dose-related 
increases in epidermal thickness and to induce granular layer 
form ation . More recently, Elias et al [2] have demonstrated the 
"anti keratinizing" effects of retinoids in hairless mouse skin by 
morphologic and histochemical techniques and correlated these 
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findings with an assessment of abnormal water barrier function . 
In the present investigation, we selected t he hairless rhino 
mouse (hr'"hhr'"h) to evaluate and compare the antikeratinization 
potency and activity of clinically active retinoids. The skin of 
the rhino mouse contains many structural anomalies as de-
scribed in detail by Mann (23). Most conspicuous is the wrin-
kled, sagging, redundant folds of skin and the dominant pres-
ence of keratinized pilosebaceous structures (horn-filled utri-
culi) as compared to the smooth-skinned hairless (hr hr) allele. 
Using conventional qualitative histologic techniques, Van Scott 
[24] and more recently Kligman and Kligman [25], reported 
that topical all -trans-retinoic acid normalized altered epithelia l 
structures in rhino mouse skin. 
The objective of this study was to evaluate the anti keratin-
izing effects of clinically active retinoids after their topical or 
oral administration by measuring the reduction in s ize of horn -
filled utriculi in rhino mouse skin. A technique to quantify the 
size of horn -filled utriculi in rhino mouse epidermis is described. 
This model represents a novel method to determine potency 
differences among biologically active antikeratinizing retinoids. 
MATERIALS AND METHODS 
AnimaL~ 
Hairless rhino (hrhhrh) mice were obtained from the Skin and 
Cancer Hospital of Temple Un iversity Health Sciences Center, Phila· 
delphia, Pennsylvania. The mice were 6- 8 weeks old at the beginning 
of the study. 
Test Retinoids 
Tretinoin (all -trans-RA), isotretinoin (13-cis-RA), motretinide (Ro 
11 -1430), and etretinate (Ro 10-9359) were obtained from Hoffmann· 
LaRoche, Nutley, New Jersey. Each crystalline compound was pro· 
tected from light and stored between -10·C and - 20·C. For topical 
application, each retinoid was dissolved in an alcohol:propylene glycol 
vehicle (70:30, v/v) while suspensions of each compound in sesame oil 
were prepared for oral (p.o.) dosing. Test retinoids were freshly pre· 
pared and protected from light prior to each daily treatment. 
For topical application, test retinoid solutions (100 ).II) were spread 
evenly over the entire dorsal trunk of each rhino mouse by means of 
an automatic microliter pipet once daily, 5 consecutive days per week 
for 2 weeks. Retinoid suspensions in sesame oil were administered b,' 
oral gavage (5 ml/kg) once daily, 5 consecutive days per week for 3 
weeks. 
Whole Mount Epiderm~~ Technique 
Approximately 72 h following final topical or oral treatment, the 
mice were sacrificed by cervical dislocation. The dorsal trunk skin was 
removed and placed into 0.5% acetic ac id for approximately 18 h at 4·-
G· C for whole mount processing. An area of skin, approximately 2 x 5 
cm, was partitioned with a blade and the epidermis was carefully peeled 
using a flat-end spatula and fine forceps. The removed epidermis was 
placed on a glass slide with the dermal side facing up, cleared in 
alcohol/xylene, and coverslipped with Permount for microscopic eval· 
uation. 
Microscopic Measu.rements 
For each whole mount, the diameters of 10 utriculi in 5 random 
fields were measured with an Optomax Image Analysis System (Opto' 
max Inc., Hollis, New Hampshire) to compare the effects of test retinoid 
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FIG 2. Topical dose· response relationship of retinoids on ut riculus 
size reduction in the rhino mouse. Vehicle control (A). Top panel, all · 
trans-RA (e) and 13·cis-RA (0). Middle panel, all-trans·RA (e) a nd 
etretinate (0). Lower panel, all ·trans· RA (e) and motretinide (6). 
preparations to vehicle control. The mean utriculus diameter was 
calculated for each treatment group. 
FIG 1. Horn ·fi lled utriculi in topi · 
ca lly t reated rhino mouse skin (10 dai ly 
applications). A, Vehicle control. B, Re· 
duction with 0. 1 % all- trans-RA. Bars = 
100/Lm. 
TABLE L Topical potency of various retinoids on utriculus reduction 
in rhino mouse epidermis 
Retinoid 
all-trans·Retinoic acid 
13-cis· Retinoic acid 
Etretinate 
Motretinide 
0.005' 
0.021 
0.07 
0.181 
Relative potencies 
(95% C.L)' 
1.00 
0.27 (0.14, 0.50)" 
0.08 (0.05, 0.13)" 
0.02 (0.007, 0.031)" 
a A minimum of 4 doses was used to generate each dose-response 
curve. 
b C.I. , confidence interval. 
, In 2 additional repetit ions of this assay, ED:;o values of 0.004 and 
0.007 were obta ined and no significant (p > 0.05) difference exists 
between these va lues. 
" Statistically less potent than a ll -trans- retinoic ac id. 
Analysis of Data 
Percent ED"" values and re lative potencies were calculated by using 
a parallel line bioassay with t he common slopes of each compound 's 
dose· response data compared with that of all-trans·RA [26]. The dif· 
ferences among the various treatment groups were evaluated using a 
Dunnett's two-tailed t-test [27 ]. 
RESULTS AND DISCUSSION 
The earlier techniques to evaluate agents on rhino mouse 
skin for their effects on keratinizat ion and exfoliation utilized 
histologic vertical sections [24,25). In the rhino mouse model 
described here, epidermal sheets suitable for microscopic meas-
urement were obtained by acetic acid splitting and alcohol/ 
xylene clearing. Numerous circular-shaped utriculi were re-
vea led in rhino mouse epidermis (Fig 1A). The mean utriculus 
diameters ± SEM in 3 separate experiments for each group of 
5 topically t reated vehicle control mice were 175.1 ± 3.5, 185.7 
± 7.2, and 206.0 ± 12.7 !lm . 
All topically tested retinoids produced significant dose-re-
lated reductions in the size of horn-filled utriculi in rhino mouse 
skin. The effects with 0.1 % all-trans-RA are shown in Fig lB. 
Dose-response regression lines and EDr,o values from 3 separate 
experiments comparing all-trans-RA, 13-cis-RA, etretinate, and 
motretinide are plotted in Fig 2. The EDr,o value is defined as 
that dose which reduced the diameter of utriculus size by one-
half relative to the mean ut riculus diameter of vehicle control 
animals. In each experiment, consistent ED 50 values (.004, .005, 
.007) and reductions in utriculus size at each dose tested were 
obtained with all-trans-RA. 
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TABLE II. Oral (p.o.) activity of various retinoirfs on utriculus reduction in rhino mouse epidermis 
-----------------P~e-rc-en-t-------
Treatment" 
Vehicle control 
all -trans-Retinoic acid 
13·cis- Retinoic acid 
Etretinate 
Mot retin ide 
" Reti noids suspended in sesame oil vehicle. 
b Data pooled from 3 experiments. 
< Data pooled from 2 experi ments. 
d p < 0.05 vs vehicle cont rol. 
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FIG 3. Oral dose-response relationship of all -t ran.s-RA (e) and 13-
cis- RA (0 ) on utriculus size reduction in the rhino mouse. Vehicle 
control (A). 
Table I summa rizes t he topical ED!io values and relative 
potency ra nking of all -trans-RA, 13-cis-RA, etretinate, a nd 
motretinide on ut r iculus s ize reduction . For t he determination 
of relative pote ncy values, all -trans- RA was compared to each 
compound by using a common slope. As can be seen from T able 
I, all -trans-RA is 3.7 t imes more poten t t ha n 13-cis- RA, while 
be ing 12.5 a nd 50 t imes more poten t than etretinate a nd 
motretinide, respectively. These experimenta l data of relative 
pote ncy on follicula r keratinization appear to be clinica lly 
relevant, s ince in comparative clinical acne studies, 0.05% a ll -
trans-RA was reported to be superior to 0.1 % motret inide in 
reducing t he number of comedones [1 4). 
In addi t ion to topical activity , ora lly administered retinoids 
(5 mg/kg) s ignificant ly reduced ut riculus s ize in rhino mouse 
skin (Table II). In t his experiment, all retinoids produced a 
statistically significan t reduction in ut riculus s ize. Also, at t he 
5 mg/kg dose tested , all-trans-RA was more active than the 
other t hree retinoids. The ora l dose- response regression curves 
a nd ED"" values for all -trans-RA and 13-cis- RA on utriculus 
s ize reduction are depict ed in Fig 3. Both isomers produced 
dose-re lated equiactive effects. At t he 10 mg/kg dose, a 48.4% 
and 47.0% reduction in ut riculus s ize was obta ined wi t h all· 
trans- RA and 13-cis-RA, respectively. Although ora lly equiac-
t ive, all -trans-RA was calculated to be 2.3 t imes more poten t 
t ha n 13-cis- RA. Recent clinical evidence [28) suggests that in 
additio n to causing a reduction in sebaceous gland activity, ora l 
13-cis-RA also a ffects follicular keratinizat ion in acne pat ients. 
T hese clinical data on reducing follicular hyperkeratinization 
in huma ns concur wi t h t he data ob tained in our studies using 
t he rhino mouse model. 
reduction 
46.2d 
27.4d 
31.7d 
33.1 d 
T he ut riculus s ize reduction p roduced by t he retinoids in t his 
study correlated very nicely wit h our histologic (vertical sec-
tions) observations (29) a nd t hose reported earlier by Va n Scott 
(24) a nd K ligman and Kligma n [25 ) which revealed exfoliation 
of horn -fi lled u t riculi a nd normalization of altered epit helial 
structures in rhi no mouse skin treated wi t h all -trans-RA. 
In summary, t he rhino mouse model described in this report 
represents a useful in vivo assay to quantify t he anti kera tinizing 
potency and activi ty of biologically active retinoids and holds 
pro'nise to ident ify potentially useful topical o r systemic agen ts 
r de rmatologic disorders of keratinization . 
''"Ie authors wish to thank Mrs. Margaret Westlake fo r her help in 
t.he preparation of this manuscript . 
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